Graybug Vision, Inc. (GRAY) Stock Analysis

Graybug Vision, Inc. (GRAY) Healthcare & Pipeline Overview

Graybug Vision, Inc., a clinical-stage biopharmaceutical company with a market cap of $121M, focuses on developing innovative therapies for retinal and optic nerve diseases. Its lead candidate, GB-102, targets wet age-related macular degeneration and diabetic macular edema, positioning the company within the competitive biotechnology landscape.

What Is the Investment Thesis for GRAY?

Graybug Vision's investment thesis centers on the potential of its lead product candidate, GB-102, to address significant unmet needs in the treatment of wet AMD and DME. Positive results from ongoing Phase I/IIa and IIb clinical trials for wet AMD, and the Phase IIa clinical trial for DME, could serve as major catalysts. The company's focus on sustained delivery through its microparticle depot formulation offers a potential competitive advantage. However, the company's success is contingent on navigating the inherent risks of clinical development, including regulatory hurdles and potential setbacks in trial outcomes. With a market cap of $121M and a beta of 1.20, GRAY presents a high-risk, high-reward investment opportunity within the biotechnology sector.

Based on FMP financials and quantitative analysis

GRAY Key Highlights

Lead product candidate GB-102 is in Phase I/IIa and IIb clinical trials for wet age-related macular degeneration.

• GB-102 is also in Phase IIa clinical trial for diabetic macular edema.
• Developing GB-102 for the treatment of diabetic retinopathy.
• Developing GB-401 for the treatment of primary open-angle glaucoma.
• The company has 8 employees.

Who Are GRAY's Competitors?

GRAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GRAY's Key Strengths?

Innovative sustained-release drug delivery technology.

• Pipeline of product candidates targeting major retinal diseases.
• Experienced management team with expertise in drug development.

What Are GRAY's Weaknesses?

Clinical-stage company with no currently marketed products.

• Reliance on successful clinical trial outcomes and regulatory approvals.
• Limited financial resources compared to larger pharmaceutical companies.

What Could Drive GRAY Stock Higher?

Announcement of Phase IIb clinical trial results for GB-102 in wet AMD.

• Initiation of Phase III clinical trials for GB-102 in wet AMD, pending Phase IIb results.
• Progression of Phase IIa clinical trial for GB-102 in diabetic macular edema.
• Continued development of GB-401 for primary open-angle glaucoma.

What Are the Key Risks for GRAY?

Financial-distress signal — its Altman Z-Score of -9.56 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Unfavorable results from clinical trials for GB-102 or GB-401.
• Delays in regulatory approval process.
• Competition from other companies developing therapies for retinal diseases.
• Dependence on securing additional funding to support clinical development.

What Are the Growth Opportunities for GRAY?

• GB-102 for Wet AMD: The wet AMD market is a significant growth opportunity, driven by the aging population. GB-102's sustained-release formulation could reduce the frequency of intravitreal injections, a major burden for patients. Success in Phase IIb trials and subsequent regulatory approval could capture a substantial share of this market, projected to reach $12 billion by 2028.
• GB-102 for DME: Diabetic macular edema represents another substantial market opportunity. GB-102's potential to provide sustained efficacy with fewer injections could be a key differentiator. Positive results from the Phase IIa trial and further development could position Graybug Vision as a significant player in the DME treatment landscape, estimated at $4.5 billion by 2027.
• GB-102 for Diabetic Retinopathy: Expanding the application of GB-102 to diabetic retinopathy presents a further growth avenue. The increasing prevalence of diabetes globally is driving the demand for effective treatments.
• GB-401 for Glaucoma: The development of GB-401 for primary open-angle glaucoma addresses a large and growing market. The implant formulation offers the potential for long-term IOP control, reducing the need for daily eye drops. Successful clinical trials and regulatory approval could establish Graybug Vision in the glaucoma treatment space, projected to be worth $5.9 billion by 2028.
• Partnerships and Licensing: Strategic partnerships with larger pharmaceutical companies or licensing agreements for its product candidates could provide Graybug Vision with significant financial resources and accelerate the development and commercialization of its pipeline. This could also validate the company's technology and increase its visibility within the industry.

What Threats Does GRAY Face?

• Competition from existing and emerging therapies.
• Unsuccessful clinical trial outcomes.
• Regulatory delays or rejection of product candidates.

What Are GRAY's Competitive Advantages?

• Proprietary sustained-release drug delivery technology.
• Patent protection for GB-102 and GB-401.
• Clinical trial data supporting the efficacy and safety of its product candidates.

What Does GRAY Do?

Graybug Vision, Inc., founded in 2011 and based in Redwood City, California, is a clinical-stage biopharmaceutical company dedicated to developing transformative medicines for diseases affecting the retina and optic nerve. Originally incorporated as Graybug LLC, the company rebranded in 2016 to Graybug Vision, Inc. The company's primary focus is on addressing unmet needs in the treatment of prevalent vision-threatening conditions. Their lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib. GB-102 is currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration (wet AMD) and a Phase IIa clinical trial for diabetic macular edema (DME). Additionally, Graybug Vision is developing GB-102 for diabetic retinopathy and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor, for primary open-angle glaucoma. These product candidates represent the company's commitment to providing sustained and targeted therapies for chronic eye diseases, potentially reducing the treatment burden for patients and improving visual outcomes.

What Products and Services Does GRAY Offer?

• Develop medicines for diseases of the retina and optic nerve.
• Focus on sustained-release drug delivery technologies.
• Develop GB-102, an intravitreal injection for wet age-related macular degeneration.
• Develop GB-102 for diabetic macular edema.
• Develop GB-102 for diabetic retinopathy.
• Develop GB-401, an intravitreally injected implant for primary open-angle glaucoma.

How Does GRAY Make Money?

• Develops pharmaceutical products for retinal and optic nerve diseases.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through product sales, licensing fees, and milestone payments.

What Industry Does GRAY Operate In?

Graybug Vision operates within the biotechnology industry, specifically targeting the ophthalmology market. This market is characterized by a growing prevalence of age-related macular degeneration, diabetic retinopathy, and glaucoma, driven by an aging global population and increasing rates of diabetes. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel therapies for these conditions. Graybug Vision aims to differentiate itself through its sustained-release drug delivery technologies, potentially offering improved efficacy and reduced treatment frequency compared to existing therapies.

Who Are GRAY's Key Customers?

• Patients with wet age-related macular degeneration.
• Patients with diabetic macular edema.
• Patients with diabetic retinopathy.
• Patients with primary open-angle glaucoma.

Key Financial Metrics

Its free cash flow yield is -15.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.58 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.0%, the inverse of the P/E and a quick read on earnings relative to price.

Graybug Vision, Inc. (GRAY) Valuation Context

Valued at $121M, GRAY is classified as a micro-cap stock.

Company Profile

Graybug Vision, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Frederic Guerard. GRAY has traded publicly since 2020.

Graybug Vision, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.56 places it in the distress zone, a signal of elevated financial risk.

Graybug Vision, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 1430.4% below estimates on average.

The most recent 12 insider filings for Graybug Vision, Inc. break down as 0 sales and 12 purchases. On net that is roughly 73K shares acquired (about $206K) — insiders putting money in tends to read as conviction.

GRAY Financials

GRAY Latest News

What Investors Ask About Graybug Vision, Inc. (GRAY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources